TECH,- A new benchmark for artificial intelligence in medicinal chemistry is testing whether models can interpret molecular diagrams, explain experimental evidence and choose promising compounds for further study. OpenAI introduced MedChemBench on 20 November, aiming to measure skills that matter in the early stages of drug research. Its results are encouraging in some areas, but the researchers explicitly warn that a strong benchmark score does not prove an AI system can discover new medicines.
The research announcement describes 99 problems assembled from 117 published papers and patents, involving 761 distinct molecular structures. Models receive information available at a selected stage of a historical research project, then attempt to reason about compounds and experiments whose later outcomes can be checked.
Why medicinal chemistry is difficult to automate
Developing a useful drug candidate involves trade-offs. A molecule might bind strongly to a target protein but fail to enter cells efficiently. Another might reach its destination but break down too quickly in the body. Researchers must consider several characteristics at once before deciding which compounds deserve the cost and time of further experiments.
This makes medicinal chemistry different from a straightforward fact-retrieval task. A model needs to read a structure correctly, understand the evidence and make choices under uncertainty. Misreading the position of an atom or the shape of a ring can turn a plausible chemical explanation into one about the wrong substance.
MedChemBench evaluates four broad abilities: reconstructing molecular structures, explaining findings, ranking or selecting compounds, and predicting their measured properties. The scores do not carry the same meaning across every component, so they should be interpreted separately rather than compressed into a single claim that the model is a competent scientist.
What the first results show
At a particularly high reasoning setting, OpenAI reports that GPT-6.2 Astra earned 84.5 per cent of the available credit, compared with 83.3 per cent for GPT-6 Astra and 82.0 per cent for GPT-6.1 Sol. The report also found that compound selection and numerical property prediction remained substantially harder than interpreting structures or explaining experimental evidence.
These figures come from the benchmark developer’s own evaluation and have limitations. The tasks were based on existing research, so prior exposure to published material cannot be ruled out. The tests also involved individual model attempts rather than full laboratory campaigns using new measurements and iterative feedback.
Why the gap matters for real research
A scientist needs more than a convincing explanation of results already known. Early drug development requires choosing a compound that is worth making, deciding which experiment to run and interpreting unexpected findings. A laboratory must still synthesise substances, measure properties and assess safety. Incorrect suggestions can waste resources or create risks if they are trusted without review.
AI may nevertheless become useful as a research assistant: reading chemical literature, organising data or proposing hypotheses for experts to test. The value of such assistance should be measured through blinded studies and actual experimental outcomes, not only retrospective problem solving.
The implications for Asia’s life-sciences sector
Singapore and other Asian research hubs have strong interests in biotechnology and pharmaceutical development. Better tools for handling chemical evidence could assist institutions with limited time and specialised expertise. They may also create new needs for validation standards, secure research data and interdisciplinary skills.
The research release listing places MedChemBench alongside efforts to evaluate AI in science. The important next step is independent testing on genuinely new research tasks. For now, the benchmark clarifies where AI reasoning is advancing and where scientists must remain cautious.